Mga Batayang Estadistika
| LEI | 549300CHIMT2EUSNJB60 |
| CIK | 1157601 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Madrigal Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 5, 2025 |
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates •Second-quarter 2025 Rezdiffra™ (resmetirom) net sales of $212. |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Comm |
|
| August 5, 2025 |
dated as of April 24, 2025, by and between Madrigal Pharmaceuticals, Inc. and KPG FF Owner, L.P. Exhibit 10.3 LEASE AGREEMENT KPG FF Owner, L.P. Landlord AND Madrigal Pharmaceuticals, Inc. Tenant AT 1001 Conshohocken State Road West Conshohocken, Pennsylvania 19428 LEASE AGREEMENT INDEX 1. Basic Lease Terms and Definitions. 1 2. Premises. 4 3. Use. 5 4. Term; Possession. 6 5. Rent. 6 6. Operating Expenses; Property Taxes. 6 7. Services. 8 8. Insurance; Waivers; Indemnification. 8 9. Maintenan |
|
| August 5, 2025 |
etter Agreement, dated April 16, 2025, by and between Madrigal Pharmaceuticals, Inc. and Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND REPLACED WITH “[***]” BECAUSE IT IS NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Four Tower Bridge 200 Barr Harbor Drive, Suite 200 West Conshohocken, PA 19428 April 14, 2025 Dr. Rebecca Taub Dear Becky: I am pleased to offer you the new role of Senior Scientific Advisor for Madrigal Pharma |
|
| August 5, 2025 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND REPLACED WITH “[***]” BECAUSE IT IS NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Four Tower Bridge 200 Barr Harbor Drive, Suite 200 West Conshohocken, PA 19428 February 12, 2025 David Griffith Soergel, Jr., M.D. Dear David: I am pleased to offer you the position of Executive Vice President, |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission fil |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Commi |
|
| July 30, 2025 |
Exhibit 99.1 Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited · License agreement supports Madrigal’s pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra™ (resmetirom) · Combining Rezdiffra with the oral GLP-1, SYH2086, offers potential f |
|
| July 22, 2025 |
Exhibit 99.1 Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH •Proceeds to primarily support MASH pipeline expansion and to refinance existing senior credit facility •$350 million initial term loan funded at close and up to an additional $150 million available through 2027 •Agreement also provides for t |
|
| July 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2025 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Commi |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2025 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Commi |
|
| June 20, 2025 |
As filed with the Securities and Exchange Commission on June 20, 2025 As filed with the Securities and Exchange Commission on June 20, 2025 Registration No. |
|
| June 20, 2025 |
Form of Performance-Based Restricted Stock Unit Award Agreement Exhibit 99.5 MADRIGAL PHARMACEUTICALS, INC. 2025 INDUCEMENT STOCK PLAN FORM OF market Stock Unit Award Grant Notice 1. Name of Participant: [●] 2. Grant Date of the MSUs (the “Grant Date”): [●] 3. Target Number of MSUs: [●] 4. Maximum Number of MSUs: [●] 5. Performance Period: The period commencing on [] and ending on [] (subject to Section 5 of the Market Stock Unit Agreement (the “Performance Pe |
|
| June 20, 2025 |
Calculation of Filing Fee Tables S-8 MADRIGAL PHARMACEUTICALS, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.0001 par value per share Other 100,000 $ 280.85 $ 28,085,000.00 0.0001531 $ 4,299.81 |
|
| June 20, 2025 |
Exhibit 99.1 MADRIGAL PHARMACEUTICALS, INC. 2025 INDUCEMENT STOCK PLAN 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Madrigal Pharmaceuticals, Inc. 2025 Inducement Stock Plan, have the following meanings: “Administrator” means the Board of Directors, unless it has delegated power to act on its behalf to the Committe |
|
| June 20, 2025 |
Form of Non-Qualified Stock Option Agreement Exhibit 99.2 MADRIGAL PHARMACEUTICALS, INC. 2025 INDUCEMENT STOCK PLAN NON-QUALIFIED STOCK OPTION AGREEMENT GRANT NOTICE 1. Name of Participant: 2. Grant Date of the Option (the “Grant Date”): 3. Number of Shares of Common Stock Covered by the Option: 4. Purchase Price Per Share of Common Stock: 5. Vesting Commencement Date: 6. Vesting of Award: Subject to the Participant’s continuous employment o |
|
| June 20, 2025 |
Form of Restricted Stock Unit Award Agreement (Non-Section 16 Officers) Exhibit 99.3 Non-Section 16 Officer Form MADRIGAL PHARMACEUTICALS, INC. 2025 INDUCEMENT STOCK PLAN RESTRICTED Stock Unit Award Grant Notice 1. Name of Participant: 2. Grant Date of the RSUs (the “Grant Date”): 3. Number of RSUs: 4. Vesting of Award: Subject to the Participant’s continuous employment or other service relationship with or to the Company or any of its Affiliates as an employee, direc |
|
| June 20, 2025 |
Form of Restricted Stock Unit Award Agreement (Section 16 Officers) Exhibit 99.4 Section 16 Officer Form MADRIGAL PHARMACEUTICALS, INC. 2025 INDUCEMENT STOCK PLAN RESTRICTED Stock Unit Award Grant Notice 1. Name of Participant: 2. Grant Date of the RSUs (the “Grant Date”): 3. Number of RSUs: 4. Vesting of Award: Subject to the Participant’s continuous employment or other service relationship with or to the Company or any of its Affiliates as an employee, director, |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2025 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Commiss |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission fi |
|
| May 1, 2025 |
Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates Exhibit 99.1 Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates •First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million •As of March 31, 2025, more than 17,000 patients on Rezdiffra •Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as oral late-breaker at EASL Congress (May 7-10) •Appointed David So |
|
| April 29, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2025 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Comm |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2025 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Commi |
|
| March 11, 2025 |
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors Exhibit 99.1 Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors • Fred Craves, Ph.D. to retire from Madrigal’s Board of Directors in July 2025 CONSHOHOCKEN, Pa., Mar. 11, 2025 – Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appo |
|
| February 26, 2025 |
DOCUMENT TITLE: Insider Trading Policy Exhibit 19.1 I.Purpose of Policy The purchase or sale of securities while possessing material nonpublic (“inside”) information or the disclosure of inside information (“tipping”) to others who may trade in such securities is sometimes referred to as “insider trading”. Illegal insider trading occurs when a person buys or sells a security when in possession of |
|
| February 26, 2025 |
ourth Amendment to Office Lease. Exhibit 10.29 FOURTH AMENDMENT TO LEASE THIS FOURTH AMENDMENT TO LEASE (this "Amendment") is made and entered into as of May 30, 2023, by and between BARR HARBOR DRIVE, LLC, a Pennsylvania limited liability company ("Landlord"), successor in interest to Four Tower Bridge Associates, and MADRIGAL PHARMACEUTICALS, INC., a Delaware corporation ("Tenant"). A.Landlord and Tenant are parties to a Lease |
|
| February 26, 2025 |
Exhibit 99.1 Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis • Fourth-quarter and full-year 2024 Rezdiffra net sales of $103.3 million and $180.1 million, respectively • As of year-end 2024, more than 11,800 patients on Rezdiffr |
|
| February 26, 2025 |
ect to corporate headquarters facility located in West Conshohocken Exhibit 10.25 LEASE This lease (“LEASE”) is entered into as of 1/10/2019 between Four Tower Bridge Associates, a Pennsylvania limited partnership (“LANDLORD”), and Madrigal Pharmaceuticals, Inc., a Delaware corporation (“TENANT”). In consideration of the mutual covenants stated below, and intending to be legally bound, Landlord and Tenant covenant and agree as follows: 1.KEY DEFINED TERMS. (a)"Aba |
|
| February 26, 2025 |
Exhibit 10.32 Tenant: Madrigal Pharmaceuticals, Inc. SEVENTH AMENDMENT TO LEASE This Seventh Amendment to Lease ("Amendment") is made and entered into as of this 2nd day of May 2024, by and between BARR HARBOR DRIVE, LLC, a Pennsylvania limited liability company ("Landlord") and MADRIGAL PHARMACEUTICALS, INC., a Delaware corporation ("Tenant"). A.Landlord and Tenant are parties to that certain Lea |
|
| February 26, 2025 |
inth Amendment to Office Lease. Exhibit 10.34 Tenant: Madrigal Pharmaceuticals, Inc. NINTH AMENDMENT TO LEASE This Ninth Amendment to Lease (“Amendment”) is made and entered into as of the 15 day of October 2024, by and between BARR HARBOR DRIVE, LLC, a Pennsylvania limited liability company (“Landlord”) and MADRIGAL PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). A.Landlord and Tenant are parties to that certain Lease |
|
| February 26, 2025 |
Exhibit 10.26 Tenant: Madrigal Pharmaceuticals, Inc. Premises: Four Tower Bridge, Suite 200 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO. LEASE ("Amendment") is made and entered into as of 7/17/2020 , by and between FOUR TOWER BRIDGE ASSOCIATES, a Pennsylvania limited partnership ("Landlord"), and MADRIGAL PHARMACEUTICALS, INC., a Delaware corporation ("Tenant"). A.• Landlord and Tenant are pa |
|
| February 26, 2025 |
Exhibit 10.27 Tenant: Madrigal Pharmaceuticals, Inc. Premises: Four Tower Bridge, Suite 200 & Suite 250 SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE ("Amendment") is made and entered into as of 5/3/2021 by and between FOUR TOWER BRIDGE ASSOCIATES, a Pennsylvania limited partnership ("Landlord"), and MADRIGAL PHARMACEUTICALS, INC., a Delaware corporation ("Tenant"). A.Landlord and Tenan |
|
| February 26, 2025 |
Sixth Amendment to Office Lease. !;:· Exhibit 10.31 Tenant: Madrigal Pharmaceuticals, Inc. SIXTH AMENDMENT TO LEASE This Sixth Amendment to Lease ("Amendment") is made and entered into as of the 16th day of April 2024, by and between BARR HARBOR DRNE, LLC, a Pennsylvania limited liability company ("Landlord") and MADRIGAL PHARMACEUTICALS, INC., a Delaware corporation ("Tenant"). A.Landlord and Tenant are parties to that certain L |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33 |
|
| February 26, 2025 |
Exhibit 10.35 CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND REPLACED WITH “[***]” BECAUSE IT IS NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Execution Copy COMMERCIAL SUPPLY AGREEMENT This Commercial Supply Agreement (this “Agreement”) is made effective as of August 21, 2023 (the “Effective Date”) by and between Madrigal Pharmaceuticals, Inc. a Del |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (C |
|
| February 26, 2025 |
ifth Amendment to Office Lease. Exhibit 10.30 Tenant: Madrigal Pharmaceuticals, Inc. Premises: Four Tower Bridge Suites 100, 200, 250 and 255 FIFTH AMENDMENT TO LEASE This Fifth Amendment to Lease (“Amendment”) is made and entered into as of the 31st day of August 2023, by and between BARR HARBOR DRIVE, LLC, a Pennsylvania limited liability company (“Landlord”), successor in interest to Four Tower Bridge Associates, and MADRIGAL |
|
| February 26, 2025 |
hird Amendment to Office Lease. Exhibit 10.28 Tenant: Madrigal Pharmaceuticals, Inc. Premises: Four Tower Bridge, Suites 200, 250 & Suites 100 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this “Amendment”) is made and entered into as of March 8 , 2022, by and between FOUR TOWER BRIDGE ASSOCIATES, a Pennsylvania limited partnership (“Landlord”), and MADRIGAL PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). A.L |
|
| February 26, 2025 |
Exhibit 10.33 Tenant: Madrigal Pharmaceuticals, Inc. EIGHTH AMENDMENT TO LEASE This Eighth Amendment to Lease (“Amendment”) is made and entered into as of the day of August 2024, by and between BARR HARBOR DRIVE, LLC, a Pennsylvania limited liability company (“Landlord”) and MADRIGAL PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). A.Landlord and Tenant are parties to that certain Lease d |
|
| February 26, 2025 |
Exhibit 21.1 Subsidiaries Set forth below is a list of subsidiaries of the Registrant as of December 31, 2024 Name Jurisdiction of Incorporation Madrigal Pharmaceuticals BV Netherlands Madrigal Pharmaceuticals GmbH Switzerland Madrigal Pharmaceuticals EU Ltd. Ireland Synta Limited United Kingdom Madrigal Pharmaceuticals GmbH Germany Canticle Pharmaceuticals, Inc. Delaware |
|
| February 26, 2025 |
Resmetirom Commercial Supply Agreement, dated as of December 23, 2024, by and between Evo Exhibit 10.36 CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND REPLACED WITH “[***]” BECAUSE IT IS NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Execution Copy RESMETIROM COMMERCIAL SUPPLY AGREEMENT RECITALS 1 Article 1 DEFINITIONS. 1 Article 2 TERM AND RENEWAL. 2 Article 3 SUPPLY OF PRODUCT. 3 Article 4 PRODUCT PRICE. 14 Article 5 QUALITY & REGULATORY |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Co |
|
| January 13, 2025 |
Exhibit 99.1 Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra • Preliminary fourth-quarter and full-year 2024 Rezdiffra™ (resmetirom) net sales ranges of $100 million to $103 million and $177 million to $180 million, respectively • Preliminary year-end 2024 cash, cash equivalents, restricted cash and marketab |
|
| November 14, 2024 |
MDGL / Madrigal Pharmaceuticals, Inc. / RTW INVESTMENTS, LP Passive Investment SC 13G 1 p24-3253sc13g.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Madrigal Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 558868105 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the appropriate |
|
| November 14, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99 2 p24-3253exhibit99.htm JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K) EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without t |
|
| November 14, 2024 |
MDGL / Madrigal Pharmaceuticals, Inc. / PAULSON & CO. INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Madrigal Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 558868105 (CUSIP |
|
| October 31, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Madrigal Pharmaceuticals, Inc. |
|
| October 31, 2024 |
ment, dated January 3, 2024, by and between Madrigal Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND REPLACED WITH “[***]” BECAUSE IT IS NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Four Tower Bridge 200 Barr Harbor Drive, Suite 200 West Conshohocken, PA 19428 January 3, 2024 Shannon Kelley [*personally identifiable information*] Dear Shannon: I am pleased to offer you the position of Chie |
|
| October 31, 2024 |
As filed with the Securities and Exchange Commission on October 31, 2024 S-8 As filed with the Securities and Exchange Commission on October 31, 2024 Registration No. |
|
| October 31, 2024 |
formxex102herculesamendm Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND REPLACED WITH “[***]” BECAUSE IT IS NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Execution Version SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is dated as of August 22, 2024 and is entered i |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Co |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissio |
|
| October 31, 2024 |
Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates EX-99.1 Exhibit 99.1 Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates • Third-quarter 2024 net sales of $62.2 million • Rezdiffra™ (resmetirom) coverage goal achieved early, with more than 80 percent of commercial lives covered; less than 5 percent of Rezdiffra-covered lives require biopsy • Completed enrollment of clinical outcomes study of Rezd |
|
| August 7, 2024 |
EX-99.1 Exhibit 99.1 Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates • Second-quarter 2024 net sales of $14.6 million • Rezdiffra™ (resmetirom) coverage in place for more than 50 percent of commercial lives; less than 5 percent of Rezdiffra-covered lives require biopsy • Expert guidelines recommend Rezdiffra as first-line therapy for patients w |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Comm |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission fil |
|
| June 27, 2024 |
Madrigal Pharmaceuticals, Inc. 2015 Amended Stock Plan, as amended and restated as of June 25, 2024. Exhibit 10.1 MADRIGAL PHARMACEUTICALS, INC. AMENDED 2015 STOCK PLAN Originally Effective June 11, 2015 Amended and Restated Effective June 29, 2017 Amended and Restated Effective June 27, 2019 Amended and Restated Effective June 17, 2021 Amended and Restated Effective June 25, 2024 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Commi |
|
| May 7, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLES FORM S-3 (Form Type) Madrigal Pharmaceuticals, Inc. |
|
| May 7, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-279168 PROSPECTUS SUPPLEMENT (To Prospectus dated May 7, 2024) $300,000,000 Common Stock We have entered into a sales agreement, or Sales Agreement, with TD Securities (USA) LLC, or TD Cowen, dated May 7, 2024, relating to the sale of shares of our common stock, par value $0.0001 per share, offered by this prospectus supplemen |
|
| May 7, 2024 |
Supplemental Compensation Recovery Policy. Exhibit 10.3 SUPPLEMENTAL COMPENSATION RECOVERY POLICY Madrigal Pharmaceuticals, Inc. Supplemental Compensation Recovery Policy Adopted by the Board of Directors (“Board”) of Madrigal Pharmaceuticals, Inc. (the “Company”) on April 26, 2024 The Board and Compensation Committee (the “Committee”) of the Board of Directors of the Company is adopting this Supplemental Compensation Recovery Policy (this |
|
| May 7, 2024 |
ales Agreement, dated May 7, 2024, by and between Mad Exhibit 1.1 MADRIGAL PHARMACEUTICALS, INC. $300,000,000 COMMON STOCK SALES AGREEMENT May 7, 2024 TD Securities (USA) LLC (dba TD Cowen) 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Madrigal Pharmaceuticals, Inc. (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees t |
|
| May 7, 2024 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND REPLACED WITH “[***]” BECAUSE IT IS NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Four Tower Bridge 200 Barr Harbor Drive, Suite 200 West Conshohocken, PA 19428 February 25, 2024 Mardi Dier [*personally identifiable information*] Dear Mardi: I am pleased to offer you employment with Madrigal |
|
| May 7, 2024 |
Exhibit 4.6 INDENTURE DATED AS OF , 20 BETWEEN MADRIGAL PHARMACEUTICALS, INC. as Issuer, AND as Trustee Providing for Issuance of Debt Securities in Series TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions. 1 Section 1.02 Compliance Certificates and Opinions. 6 Section 1.03 Form of Documents Delivered to Trustee. 6 Section 1.04 |
|
| May 7, 2024 |
Specimen Common Stock Certificate. Exhibit 4.1 COMMON STOCK COMMON STOCK PO PAR VALUE $0.0001 MR ADD ADD ADD ADD 432 1 A BOX DESIGNATION SAMPLE Certificate Shares 43004, * * 000000 ****************** (IF Number * * * 000000 ***************** ANY) ZQ00000000 **** 000000 **************** Providence, MADRIGAL PHARMACEUTICALS, INC. ***** 000000 *************** RI ****** 000000 ************** INCORPORATED UNDER THE LAWS OF THE STATE OF |
|
| May 7, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Madrigal Pharmaceuticals, Inc. |
|
| May 7, 2024 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND REPLACED WITH “[***]” BECAUSE IT IS NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Four Tower Bridge 200 Barr Harbor Drive, Suite 200 West Conshohocken, PA 19428 November 6, 2023 Carole Huntsman [*personally identifiable information*] Dear Carole: I am pleased to offer you the position of Chi |
|
| May 7, 2024 |
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates Exhibit 99.1 Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates • On March 14, 2024, received U.S. FDA approval of Rezdiffra™ (resmetirom) for the treatment of patients with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis • In April 2024, product shipped and first patients received Rezdiffra, the first and |
|
| May 7, 2024 |
As filed with the Securities and Exchange Commission on May 7, 2024 Table of Contents As filed with the Securities and Exchange Commission on May 7, 2024 Registration No. |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission fi |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Commiss |
|
| May 7, 2024 |
7,045,385 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-279168 PROSPECTUS SUPPLEMENT (To Prospectus dated May 7, 2024) 7,045,385 Shares of Common Stock This prospectus supplement relates to the possible resale, from time to time, by the selling stockholder named in this prospectus supplement of up to an aggregate of 7,045,385 shares of our common stock, which includes 1,969,797 sha |
|
| May 7, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Commiss |
|
| May 7, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(3) (Form Type) Madrigal Pharmaceuticals, Inc. |
|
| April 29, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Comm |
|
| March 25, 2024 |
MDGL / Madrigal Pharmaceuticals, Inc. / BAKER BROS. ADVISORS LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2024 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Comm |
|
| March 20, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Madrigal Pharmaceuticals, Inc. |
|
| March 20, 2024 |
750,000 Shares of Common Stock Pre-Funded Warrants to Purchase 1,557,692 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-256666 PROSPECTUS SUPPLEMENT (to Prospectus dated June 1, 2021) 750,000 Shares of Common Stock Pre-Funded Warrants to Purchase 1,557,692 Shares of Common Stock We are offering 750,000 shares of our common stock and, to certain investors, pre-funded warrants to purchase 1,557,692 shares of our common stock pursuant to this pros |
|
| March 20, 2024 |
Underwriting Agreement, dated March 18, 2024. Exhibit 1.1 Execution Version MADRIGAL PHARMACEUTICALS, INC. 750,000 Shares of Common Stock, par value $0.0001 per share Pre-Funded Warrants to Purchase 1,557,692 Shares of Common Stock Underwriting Agreement March 18, 2024 Goldman Sachs & Co. LLC Jefferies LLC Cowen and Company, LLC Evercore Group L.L.C. Piper Sandler & Co. As representatives (the “Representatives”) of the several Underwriters na |
|
| March 18, 2024 |
SUBJECT TO COMPLETION, DATED MARCH 18, 2024 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-256666 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has become effective by rule of the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Comm |
|
| March 15, 2024 |
Exhibit 99.1 Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis • Rezdiffra becomes the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”) • Accelerated approval was based on Phase 3 data demonstrating that |
|
| March 15, 2024 |
Exhibit 99.2 Rezdiffr (resmetirom) FDA Approval Conference Call March 2024 NASDAQ: MDGL © 2024 Madrigal Pharmaceuticals. All rights reserved. Forward Looking Statements This presentation includes “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that are based on Madrigal’s beliefs and assumptions and on information cu |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (C |
|
| February 28, 2024 |
Exhibit 10.20 FORM OF MADRIGAL INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of , 2024 by and between Madrigal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement. RECITALS WHEREAS, |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (C |
|
| February 28, 2024 |
Incentive Compensation Recovery Policy Exhibit 97.1 Madrigal Pharmaceuticals, Inc. Incentive Compensation Recovery Policy Adopted by the Board of Directors (“Board”) and Compensation Committee of the Board of Madrigal Pharmaceuticals, Inc. (the “Company”) on November 30, 2023 and November 29, 2023, respectively The Board and Compensation Committee (the “Committee”) of the Board of Directors of the Company is adopting this Incentive Com |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33 |
|
| February 28, 2024 |
Exhibit 99.1 Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results • Announced appointment of Mardi C. Dier as Chief Financial Officer • Anticipates resmetirom to become the first medicine approved for NASH; PDUFA date March 14, 2024 • Reports year-end 2023 cash, cash equivalents and marketable securities of $634 million CONSHOHOCKEN, P |
|
| February 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Madrigal Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 558868105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rul |
|
| February 14, 2024 |
MDGL / Madrigal Pharmaceuticals, Inc. / PAULSON & CO. INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Madrigal Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 558868105 (CUSIP |
|
| February 14, 2024 |
MDGL / Madrigal Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2024 |
MDGL / Madrigal Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01387-madrigalpharmaceutic.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Madrigal Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 558868105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate b |
|
| January 17, 2024 |
January 17, 2024 VIA EDGAR Division of Corporate Finance Office of Life Sciences U. |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Com |
|
| January 8, 2024 |
Corporate Presentation January 2024 Resmetirom is an investigational therapy and has not been approved by the FDA (or any other regulatory authority). |
|
| December 14, 2023 |
December 14, 2023 VIA EDGAR Division of Corporate Finance Office of Life Sciences U. |
|
| December 13, 2023 |
MDGL / Madrigal Pharmaceuticals Inc / BAY CITY CAPITAL LLC - SC 13D/A Activist Investment SC 13D/A 1 d510843dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Madrigal Pharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 558868105 (CUSIP Number) Susan Vuong Chief Financial Officer Bay City Capital LLC 1000 4th Str |
|
| December 8, 2023 |
December 8, 2023 VIA EDGAR Mr. Gary Newberry Mr. Kevin Kuhar Division of Corporate Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Madrigal Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 File No. 001-33277 Dear Messrs. Newberry and Kuhar: Madrigal Pharmaceuticals, Inc. (the “Company”) received a comm |
|
| November 21, 2023 |
MDGL / Madrigal Pharmaceuticals Inc / BAKER BROS. ADVISORS LP - SC 13D/A Activist Investment SC 13D/A 1 tm2331311d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Madrigal Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 558868105 (CUSIP number) Alexandra A. Toohey Chief Financial Officer Baker Bros. Advisors LP |
|
| November 13, 2023 |
MDGL / Madrigal Pharmaceuticals Inc / PAULSON & CO. INC. Passive Investment SC 13G 1 madrigal13g-11132023.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Madrigal Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class |
|
| November 6, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissio |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Co |
|
| November 6, 2023 |
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results Exhibit 99.1 Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results • Priority Review of resmetirom new drug application underway in the U.S. • Bill Sibold appointed Chief Executive Officer of Madrigal in September 2023 • $500 million financing provides Madrigal with funds to support a potential first-to-market launch of resmetirom in the U.S. • Multip |
|
| October 5, 2023 |
MDGL / Madrigal Pharmaceuticals Inc / BAKER BROS. ADVISORS LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| October 5, 2023 |
Form of Director Lock-Up Agreement. EX-99.2 2 tm2327862d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 SCHEDULE B Madrigal Pharmaceuticals, Inc. Lock-Up Agreement September 28, 2023 Goldman Sachs & Co.LLC 200 West Street New York, NY 10282-2198 Re: Madrigal Pharmaceuticals, Inc. - Lock-Up Agreement Ladies and Gentlemen: The undersigned understands that you, as representative of the Underwriters (as defined below) (the “Representative”), prop |
|
| October 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2023 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) ( |
|
| October 2, 2023 |
1,248,098 Shares of Common Stock Pre-Funded Warrants to Purchase 2,048,098 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-256666 PROSPECTUS SUPPLEMENT (to Prospectus dated June 1, 2021) 1,248,098 Shares of Common Stock Pre-Funded Warrants to Purchase 2,048,098 Shares of Common Stock We are offering 1,248,098 shares of our common stock, and, to certain investors, pre-funded warrants to purchase 2,048,098 shares of our common stock pursuant to this |
|
| October 2, 2023 |
Exhibit 4.1 to the Issuer’s Current Report on Form 8-K, filed with the SEC on October 2, 2023 Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: [ ], 2023 MADRIGAL PHARMACEUTICALS, INC. Madrigal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its register |
|
| October 2, 2023 |
Underwriting Agreement, dated September 28, 2023. Exhibit 1.1 Execution Version MADRIGAL PHARMACEUTICALS, INC. 1,248,098 Shares of Common Stock, par value $0.0001 per share Pre-Funded Warrants to Purchase 2,048,098 Shares of Common Stock Underwriting Agreement September 28, 2023 Goldman Sachs & Co. LLC As representative (the “Representative”) of the several Underwriters named in Schedule I hereto, 200 West Street, New York, New York 10282-2198 La |
|
| October 2, 2023 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Madrigal Pharmaceuticals, Inc. |
|
| September 28, 2023 |
SUBJECT TO COMPLETION, DATED September 28, 2023 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-256666 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has become effective by rule of the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell |
|
| September 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2023 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) ( |
|
| September 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2023 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (C |
|
| September 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2023 MADRIGAL PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33277 04-13508648 (State or other jurisdiction of incorporation or |
|
| September 13, 2023 |
Exhibit 10.1 EXECUTION VERSION CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND REPLACED WITH “[***]” BECAUSE IT IS NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Four Tower Bridge 200 Barr Harbor Drive, Suite 400 West Conshohocken, PA 19428 September 7, 2023 William Sibold [*personally identifiable information*] Dear William: On behalf of Madrigal Phar |
|
| September 13, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2023 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) ( |
|
| September 13, 2023 |
Exhibit 99.1 Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis CONSHOHOCKEN, PA, September 13, 2023 – Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the U.S. F |
|
| September 11, 2023 |
EX-99.1 Exhibit 99.1 MADRIGAL PHARMACEUTICALS, INC. 2023 INDUCEMENT PLAN Effective September 8, 2023 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Madrigal Pharmaceuticals, Inc. 2023 Inducement Plan, have the following meanings: “Administrator” means the Board of Directors, unless it has delegated power to act on its behal |
|
| September 11, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLES FORM S-8 (Form Type) Madrigal Pharmaceuticals, Inc. |
|
| September 11, 2023 |
Form of Stock Option Agreement under 2023 Inducement Plan EX-99.2 Exhibit 99.2 NON-QUALIFIED STOCK OPTION AGREEMENT SHARES OF COMMON STOCK, $.0001 PAR VALUE PER SHARE MADRIGAL PHARMACEUTICALS, INC. , 20 As of , 20 (the “Grant Date”), Madrigal Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, grants to (the “Participant”) the right and option (the “Option”) to purchase up to shares of the Common Stock, $.0001 par value per share, of the Compa |
|
| September 11, 2023 |
As filed with the Securities and Exchange Commission on September 11, 2023 S-8 As filed with the Securities and Exchange Commission on September 11, 2023 Registration No. |
|
| September 11, 2023 |
Form of Restricted Stock Unit Agreement under 2023 Inducement Plan EX-99.3 Exhibit 99.3 MADRIGAL PHARMACEUTICALS, INC. 2023 INDUCEMENT PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE 1. Name of Participant: 2. Grant Date of the RSUs (the “Grant Date”): 3. Number of RSUs: 4. Vesting of Award: Subject to the Participant’s continuous employment or other service relationship with or to the Company or any of its Affiliates as an Employee, director, and/or Consultant fro |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33277 MADRIGAL P |
|
| August 8, 2023 |
3,914,910 Shares of Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-256666 PROSPECTUS SUPPLEMENT (To Prospectus dated June 1, 2021) 3,914,910 Shares of Common Stock This prospectus supplement relates to the possible resale, from time to time, by the selling stockholder named in this prospectus supplement of up to an aggregate of 3,914,910 shares of our common stock, which includes 1,969, |
|
| August 8, 2023 |
EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made as of August 7, 2023 by and between Madrigal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in |
|
| August 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Comm |
|
| August 8, 2023 |
Form of RSU Agreement for Directors under Amended 2015 Stock Plan EX-10.3 Exhibit 10.3 MADRIGAL PHARMACEUTICALS, INC. AMENDED 2015 STOCK PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE 1. Name of Participant: 2. Grant Date of the RSUs (the “Grant Date”): 3. Number of RSUs: 4. Vesting of Award: Subject to the Participant’s continuous employment or other service relationship with or to the Company or any of its Affiliates as an Employee, director, and/or Consultant |
|
| August 8, 2023 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(3) (Form Type) Madrigal Pharmaceuticals, Inc. |
|
| August 8, 2023 |
Form of RSU Agreement for Executive Officers (2023) under Amended 2015 Stock Plan EX-10.4 Exhibit 10.4 Section 16 Officer Form MADRIGAL PHARMACEUTICALS, INC. AMENDED 2015 STOCK PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE 1. Name of Participant: 2. Grant Date of the RSUs (the “Grant Date”): 3. Number of RSUs: 4. Vesting of Award: Subject to the Participant’s continuous employment or other service relationship with or to the Company or any of its Affiliates as an Employee, dire |
|
| August 8, 2023 |
EX-99.1 Exhibit 99.1 Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results • Resmetirom new drug application (NDA) submitted to the U.S. Food and Drug Administration • NASH disease education and market development activities expand to support potential first-to-market launch in the U.S. CONSHOHOCKEN, PA, August 8, 2023 – Madrigal Pharmaceuticals, Inc |
|
| August 8, 2023 |
MDGL / Madrigal Pharmaceuticals Inc / BAKER BROS. ADVISORS LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 8, 2023 |
Form of RSU Agreement for Employees under Amended 2015 Stock Plan EX-10.5 Exhibit 10.5 Non-Section 16 Officer Form MADRIGAL PHARMACEUTICALS, INC. AMENDED 2015 STOCK PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE 1. Name of Participant: 2. Grant Date of the RSUs (the “Grant Date”): 3. Number of RSUs: 4. ting of Award: Subject to the Participant’s continuous employment or other service relationship with or to the Company or any of its Affiliates as an Employee, dir |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2023 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Commi |
|
| July 17, 2023 |
EX-99.1 Exhibit 99.1 Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis CONSHOHOCKEN, PA, July 17, 2023 – Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced the completion of |
|
| June 30, 2023 |
EX-99.1 Exhibit 99.1 Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis • Madrigal expects to complete full submission of the New Drug Application in July 2023 CONSHOHOCKEN, PA, June 30, 2023 – Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutic |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Commi |
|
| June 20, 2023 |
EX-3.1 EXHIBIT 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION MADRIGAL PHARMACEUTICALS, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Madrigal Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under the laws of the State of Delaware, does hereby certify: 1. This Certificate of Amendment (the “Certificate |
|
| June 20, 2023 |
Agreement Regarding the Joint Filing of Schedule 13D by and among the Reporting Persons. Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of the shares of Common Stock of Madrigal Pharmaceuticals, Inc. This Agreement may be executed in any nu |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or another jurisdiction of incorporation) (Com |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Commi |
|
| June 20, 2023 |
MDGL / Madrigal Pharmaceuticals Inc / BAKER BROS. ADVISORS LP - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 9, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Madrigal Pharmaceuticals, Inc. |
|
| May 9, 2023 |
Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results EX-99.1 Exhibit 99.1 Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results • Resmetirom new drug application (NDA) filing on track for Q2 2023 • Resmetirom has received Breakthrough Therapy designation from FDA • Multiple resmetirom abstracts accepted for presentation at EASL, including primary results and additional data from the Phase 3 MAESTRO-NASH |
|
| May 9, 2023 |
EX-1.1 Exhibit 1.1 AMENDMENT NO. 1 TO SALES AGREEMENT May 9, 2023 Madrigal Pharmaceuticals, Inc. Four Tower Bridge 200 Barr Harbor Drive, Suite 200 West Conshohocken, Pennsylvania 19428 Ladies and Gentlemen: Madrigal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), together with Cowen and Company, LLC (the “Agent”), are parties to that certain Sales Agreement dated June 1, 2021 (the |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33277 MADRIGAL |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Commiss |
|
| May 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Commiss |
|
| May 9, 2023 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-256666 PROSPECTUS SUPPLEMENT (To Prospectus dated June 1, 2021) $200,000,000 Common Stock We have entered into an amendment dated May 9, 2023, to our Sales Agreement with Cowen and Company, LLC, or Cowen, dated June 1, 2021, or, as amended, the Sales Agreement, relating to the sale of shares of our common stock, par valu |
|
| May 1, 2023 |
DEFA14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 1, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuan t to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| April 21, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuan t to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33277 MADRIGAL PHA |
|
| February 23, 2023 |
EX-4.3 Exhibit 4.3 DESCRIPTION OF SECURITIES OF THE REGISTRANT The following is a summary of all material characteristics of our capital stock as set forth in our restated certificate of incorporation, our restated bylaws, our Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock and our Certificate of Designation of Preferences, Rights and Limit |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33277 MADRIGAL PHARM |
|
| February 23, 2023 |
EX-99.1 Exhibit 99.1 Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results • Positive Phase 3 MAESTRO-NASH study results reported in December 2022 position Madrigal for a resmetirom new drug application filing in the first half of 2023 • Madrigal reports year end cash, cash equivalents and marketable securities of $358.8M CONSHOHOCKEN, |
|
| February 23, 2023 |
EX-21.1 Exhibit 21.1 SUBSIDIARIES OF MADRIGAL PHARMACEUTICALS, INC. Madrigal Pharmaceuticals EU Limited, an Ireland company Synta Limited Incorporated, a United Kingdom company Canticle Pharmaceuticals, Inc., a Delaware corporation |
|
| February 23, 2023 |
Form of Restricted Stock Unit Agreement under Amended 2015 Stock Plan. EX-10.12 Exhibit 10.12 MADRIGAL PHARMACEUTICALS, INC. AMENDED 2015 STOCK PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE 1. Name of Participant: 2. Grant Date of the RSUs (the “Grant Date”): 3. Number of RSUs: 4. Vesting of Award: Subject to the Participant’s continuous employment or other service relationship with or to the Company or any of its Affiliates as an Employee, director, and/or Consultan |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (C |
|
| February 14, 2023 |
MDGL / Madrigal Pharmaceuticals Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
MDGL / Madrigal Pharmaceuticals Inc / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Madrigal Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 558868105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rul |
|
| February 14, 2023 |
MDGL / Madrigal Pharmaceuticals Inc / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 9, 2023 |
EX-10.1 Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND REPLACED WITH “[***]” BECAUSE IT IS NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Execution Version FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT This FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is dated as of February 3, 2023 and is entered into by and among M |
|
| February 9, 2023 |
EX-4.1 Exhibit 4.1 CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND REPLACED WITH “[***]” BECAUSE IT IS NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDG |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2023 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Co |
|
| February 9, 2023 |
MDGL / Madrigal Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Madrigal Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 558868105 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* MADRIGAL PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 558868105 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Com |
|
| December 23, 2022 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-256666 PROSPECTUS SUPPLEMENT (to Prospectus dated June 1, 2021) 400,000 Shares of Series B Convertible Preferred Stock 44,444 Shares of Common Stock Series B Convertible Preferred Stock Common Stock We are offering 400,000 shares of our Series B convertible preferred stock, par value $0.0001 per share (the “Series B Conv |
|
| December 23, 2022 |
EX-10.2 Exhibit 10.2 AMENDMENT NO. 2 TO SECURITIES PURCHASE AGREEMENT This AMENDMENT NO. 2 TO SECURITIES PURCHASE AGREEMENT (this “Amendment”), is made and entered into as of December 22, 2022 by and among Madrigal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the Investors set forth on the signature pages affixed hereto (the “BBA Investors”). RECITALS A. The Company and the B |
|
| December 23, 2022 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (“Agreement”) is made as of the 21st day of December, 2022, by and among Madrigal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the Investors set forth on the signature pages affixed hereto (each an “Investor” and collectively the “Investors”). In consideration of the mutual promises made her |
|
| December 23, 2022 |
Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program EX-99.1 Exhibit 99.1 Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program • $259 Million in Equity Securities Sales and $50 Million in Additional Debt Financing Capacity • Madrigal intends to submit a new drug application for resmetirom in the first half of 2023 CONSHOHOCKEN, PA, December 21, 2022 – Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today a |
|
| December 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2022 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (C |
|
| December 23, 2022 |
EX-3.1 2 d434336dex31.htm EX-3.1 Exhibit 3.1 MADRIGAL PHARMACEUTICALS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Paul A. Friedman, M.D., does hereby certify that: 1. He is the Chief Executive Officer of Madrigal Pharmaceuticals, Inc., a Delaware corp |
|
| December 23, 2022 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Madrigal Pharmaceuticals, Inc. |
|
| December 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2022 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (C |
|
| November 3, 2022 |
Exhibit 99.1 Madrigal Pharmaceuticals Provides an Overview of Upcoming Resmetirom Data Presentations and Reports 2022 Third Quarter Financial Results ? Two resmetirom oral abstracts to be presented at the AASLD Liver Meeting?: ? Phase 3 MAESTRO-NAFLD-1 data demonstrate the potential of resmetirom for the treatment of patients with compensated NASH cirrhosis ? Screening data from the Phase 3 MAESTR |
|
| November 3, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Co |
|
| August 4, 2022 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND REPLACED WITH ?[***]? BECAUSE IT IS NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. EXECUTION VERSION LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of May 9, 2022 and is entered into by and among MADRIGAL PHARMACEUTICALS, INC., a Delaware corporation (?Madri |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Comm |
|
| August 4, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 4, 2022 |
Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONA |
|
| August 4, 2022 |
Exhibit 99.1 Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results ? Madrigal remains on track to announce topline data from the Phase 3 MAESTRO-NASH biopsy study in the fourth quarter CONSHOHOCKEN, PA, August 4, 2022 ? Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for |
|
| June 17, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2022 (June 15, 2022) MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or another jurisdiction of inc |
|
| May 19, 2022 |
MDGL / Madrigal Pharmaceuticals Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Commiss |
|
| May 9, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 9, 2022 |
Exhibit 99.1 Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results ? MAESTRO-NAFLD-1 late-breaker and three other Madrigal abstracts accepted for oral presentation at the EASL International Liver Congress? ? Data from the Phase 3 MAESTRO-NAFLD-1 study continue to reinforce the safety and efficacy profiles of resmetirom ? Madrigal remains o |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Commiss |
|
| May 2, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| February 24, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33 |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (C |
|
| February 24, 2022 |
Exhibit 21.1 SUBSIDIARIES OF MADRIGAL PHARMACEUTICALS, INC. Madrigal Pharmaceuticals EU Limited, an Ireland company Synta Limited Incorporated, a United Kingdom company Canticle Pharmaceuticals, Inc., a Delaware corporation |
|
| February 24, 2022 |
Exhibit 99.1 Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results CONSHOHOCKEN, PA, February 24, 2022 ? Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), today provides a summary of corporate accomplishments and repo |
|
| February 15, 2022 |
MDGL / Madrigal Pharmaceuticals Inc / ARMISTICE CAPITAL, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 15, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including additional amendments thereto) with respect to the shares of Common Stock, par value $0.0001 per share, of Madrigal Pharmaceuticals, Inc. This Joint Filing |
|
| February 14, 2022 |
MDGL / Madrigal Pharmaceuticals Inc / HealthCor Management, L.P. - SC 13G/A Passive Investment SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 3)* Madrigal Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 558868105 (CUSIP Number) December 31, 2021 (Date of Event Which Re |
|
| February 14, 2022 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT I JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. |
|
| February 11, 2022 |
SC 13G/A 1 p22-0230sc13ga.htm MADRIGAL PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Madrigal Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 558868105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of T |
|
| February 10, 2022 |
MDGL / Madrigal Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01360-madrigalpharmaceutic.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Madrigal Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 558868105 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* MADRIGAL PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 558868105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| December 7, 2021 |
MDGL / Madrigal Pharmaceuticals Inc / BAY CITY CAPITAL LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Madrigal Pharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 558868105 (CUSIP Number) Susan Vuong Chief Financial Officer Bay City Capital LLC 1000 4th Street, Suite 500 San Rafael, CA 94901 (41 |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Co |
|
| November 4, 2021 |
Exhibit 99.1 Madrigal Pharmaceuticals Provides Corporate Update and Reports 2021 Third Quarter Financial Results Several abstracts with data from the open-label arm of the Phase 3 MAESTRO-NAFLD-1 study accepted for presentation at AASLD?s upcoming The Liver Meeting? 2021 CONSHOHOCKEN, PA, November 4th, 2021 ? Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today provides a summary of corporate accomp |
|
| November 4, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Comm |
|
| August 5, 2021 |
EX-99.1 2 d211192dex991.htm EX-99.1 Exhibit 99.1 Madrigal Pharmaceuticals Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 5, 2021 Conshohocken, PA., August 5, 2021 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reports today its second quarter 2021 financial results and provides a summary of corporate accomplishments. Paul Friedman, M.D., Chief E |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33277 MADRIGAL P |
|
| July 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Madrigal Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 558868105 (CUSIP Number) June 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| June 29, 2021 |
As filed with the Securities and Exchange Commission on June 29, 2021 As filed with the Securities and Exchange Commission on June 29, 2021 Registration No. |
|
| June 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2021 (June 17, 2021) MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or another jurisdiction of inc |
|
| June 1, 2021 |
As filed with the Securities and Exchange Commission on June 1, 2021 Table of Contents As filed with the Securities and Exchange Commission on June 1, 2021 Registration No. |
|
| June 1, 2021 |
EXHIBIT 1.1 MADRIGAL PHARMACEUTICALS, INC. $200,000,000 COMMON STOCK SALES AGREEMENT June 1, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Madrigal Pharmaceuticals, Inc. (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time d |
|
| June 1, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-256666 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price(1) Amount of Registration Fee(2)(3) Common Stock, $0.0001 par value per share $200,000,000 $21,820 (1) The proposed maximum aggregate offering price is being used to calculate the registration fee |
|
| June 1, 2021 |
Exhibit 4.10 INDENTURE DATED AS OF , 20 BETWEEN MADRIGAL PHARMACEUTICALS, INC. as Issuer, AND as Trustee Providing for Issuance of Debt Securities in Series TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions. 1 Section 1.02 Compliance Certificates and Opinions. 6 Section 1.03 Form of Documents Delivered to Trustee. 6 Section 1.04 Ac |
|
| June 1, 2021 |
Specimen Common Stock Certificate. Exhibit 4.5 COMMON STOCK COMMON STOCK PO PAR VALUE $0.0001 MR ADD ADD ADD ADD 432 1 A BOX DESIGNATION SAMPLE Certificate Shares 43004, * * 000000 ****************** (IF Number * * * 000000 ***************** ANY) ZQ00000000 **** 000000 **************** Providence, MADRIGAL PHARMACEUTICALS, INC. ***** 000000 *************** RI ****** 000000 ************** INCORPORATED UNDER THE LAWS OF THE STATE OF |
|
| June 1, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Commis |
|
| June 1, 2021 |
Exhibit 4.1 DESCRIPTION OF SECURITIES OF THE REGISTRANT The following is a summary of all material characteristics of our capital stock as set forth in our restated certificate of incorporation, our restated bylaws and our Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock. Our common stock is the only class of our securities registered under |
|
| May 18, 2021 |
Alex Howarth Joins Madrigal Pharmaceuticals as Chief Financial Officer Exhibit 99.1 Alex Howarth Joins Madrigal Pharmaceuticals as Chief Financial Officer WEST CONSHOHOCKEN, Pa., May 18, 2021 ? Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need, announced today that Alex Howarth has joined Madrigal as Chief Financial Officer. ?I |
|
| May 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Commis |
|
| May 6, 2021 |
Non-Employee Director Equity Compensation Policy EXHIBIT 10.1 NON-EMPLOYEE DIRECTOR EQUITY COMPENSATION POLICY Equity Grants All grants of equity awards to non-employee directors pursuant to this Policy will be made in accordance with the following provisions: (a) Value. For purposes of this Policy, ?Value? means (i) with respect to any equity award of Madrigal, the grant date fair value (i.e., Black-Scholes Value) shall be determined in accorda |
|
| May 6, 2021 |
Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Commiss |
|
| May 6, 2021 |
Madrigal Pharmaceuticals Reports 2021 First Quarter Financial Results and Highlights EX-99.1 2 d347909dex991.htm EX-99.1 Exhibit 99.1 Madrigal Pharmaceuticals Reports 2021 First Quarter Financial Results and Highlights WEST CONSHOHOCKEN, Pa., May 6, 2021 — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its first quarter 2021 financial results and highlights. “We expect several important events for Madrigal to occur in 2021,” stated Paul Friedman, M.D., Chief Executiv |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 30, 2021 |
Definitive Proxy Statement on Schedule 14A, as filed with the SEC on April 30, 2021 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| February 25, 2021 |
Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights EX-99.1 Exhibit 99.1 Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights WEST CONSHOHOCKEN, Pa., February 25, 2021 — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its fourth quarter and full year 2020 financial results and highlights. “We are pleased with the substantial progress the Company made in 2020, particularly in light of the s |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (C |
|
| February 25, 2021 |
Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 25, 2021 |
Exhibit 21.1 SUBSIDIARIES OF MADRIGAL PHARMACEUTICALS, INC. Madrigal Pharmaceuticals EU Limited, an Ireland company Synta Securities Corp., a Massachusetts securities corporation Synta Limited Incorporated, a United Kingdom company Canticle Pharmaceuticals, Inc., a Delaware corporation |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Madrigal Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 558868105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 16, 2021 |
SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2021 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) Exhibit 99.1 EXHIBIT I JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. |
|
| February 12, 2021 |
SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 2)* Madrigal Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 558868105 (CUSIP Number) December 31, 2020 (Date of Event Which Re |
|
| February 12, 2021 |
Madrigal Pharmaceuticals, Inc. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Madrigal Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 558868105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule p |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Madrigal Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 558868105 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 4, 2021 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* MADRIGAL PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 558868105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Co |
|
| November 5, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 5, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-225434 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price(1) Amount of Registration Fee(2) Common Stock, $0.0001 par value per share $200,000,000 $21,820 (1) The proposed maximum aggregate offering price is being used to calculate the registration |
|
| November 5, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) (Co |
|
| November 5, 2020 |
EX-1.1 Exhibit 1.1 Execution Version MADRIGAL PHARMACEUTICALS, INC. $200,000,000 COMMON STOCK SALES AGREEMENT November 5, 2020 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Madrigal Pharmaceuticals, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agr |
